Suppr超能文献

ADAMTS13 构象及其在免疫性血栓性血小板减少性紫癜中的抑制机制。

ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.

机构信息

Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.

Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.

出版信息

J Thromb Haemost. 2022 Oct;20(10):2197-2203. doi: 10.1111/jth.15822. Epub 2022 Aug 3.

Abstract

ADAMTS13, a plasma metalloprotease that cleaves von Willebrand factor, is crucial for normal hemostasis. Acquired autoantibody-mediated deficiency of plasma ADAMTS13 results in a potentially fatal blood disorder, immune thrombotic thrombocytopenic purpura (iTTP). Plasma ADAMTS13 protease appears to exist in multiple conformations. Under physiological conditions, plasma ADAMTS13 exists predominantly in its "closed" conformation (or latent form), which may be activated by lowering pH, ligand binding, and binding of an antibody against the distal domains of ADAMTS13. In patients with iTTP, polyclonal antibodies target at various domains of ADAMTS13. However, nearly all inhibitory antibodies bind the spacer domain, whereas antibodies that bind the distal C-terminal domains may activate ADAMTS13 through removing its allosteric inhibition. Additionally, the anti-C-terminal antibodies may alter the potency of inhibitory antibodies towards ADAMTS13 activity. This review summarizes some of the most recent knowledge about the ADAMTS13 conformation and its mechanism of inhibition by its autoantibodies.

摘要

ADAMTS13 是一种血浆金属蛋白酶,可切割血管性血友病因子,对正常止血至关重要。获得性自身抗体介导的血浆 ADAMTS13 缺乏会导致潜在致命的血液疾病,即免疫性血栓性血小板减少性紫癜(iTTP)。血浆 ADAMTS13 蛋白酶似乎存在多种构象。在生理条件下,血浆 ADAMTS13 主要以“封闭”构象(或潜伏形式)存在,这种构象可通过降低 pH 值、配体结合以及与 ADAMTS13 远端结构域的抗体结合而被激活。在 iTTP 患者中,多克隆抗体针对 ADAMTS13 的不同结构域。然而,几乎所有的抑制性抗体都结合间隔区,而结合远端 C 末端结构域的抗体可能通过去除其变构抑制来激活 ADAMTS13。此外,抗 C 末端抗体可能改变针对 ADAMTS13 活性的抑制性抗体的效力。本综述总结了 ADAMTS13 构象及其自身抗体抑制机制的一些最新知识。

相似文献

1
ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2022 Oct;20(10):2197-2203. doi: 10.1111/jth.15822. Epub 2022 Aug 3.
2
Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
Blood. 2023 Jun 15;141(24):2993-3005. doi: 10.1182/blood.2022019252.
3
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
EBioMedicine. 2015 Jun 11;2(8):942-52. doi: 10.1016/j.ebiom.2015.06.007. eCollection 2015 Aug.
4
ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Expert Rev Hematol. 2016;9(2):209-21. doi: 10.1586/17474086.2016.1122515. Epub 2015 Dec 8.
5
Recent advances in thrombotic thrombocytopenic purpura.
Hematology Am Soc Hematol Educ Program. 2004:407-23. doi: 10.1182/asheducation-2004.1.407.
6
[anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(2):95-103. doi: 10.2177/jsci.36.95.
7
ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2024 Apr;22(4):1069-1079. doi: 10.1016/j.jtha.2023.12.028. Epub 2023 Dec 30.
8
ADAMTS13 and von Willebrand factor interactions.
Curr Opin Hematol. 2015 Sep;22(5):452-9. doi: 10.1097/MOH.0000000000000169.
9
Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2023 Dec;21(12):3402-3413. doi: 10.1016/j.jtha.2023.08.017. Epub 2023 Aug 25.
10
Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2023 Jun;21(6):1544-1552. doi: 10.1016/j.jtha.2023.02.011. Epub 2023 Feb 20.

引用本文的文献

1
Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation.
Hemasphere. 2025 Jul 27;9(7):e70189. doi: 10.1002/hem3.70189. eCollection 2025 Jul.
2
Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Antibodies (Basel). 2025 Mar 10;14(1):24. doi: 10.3390/antib14010024.
3
The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.
Int J Mol Sci. 2024 Aug 21;25(16):9055. doi: 10.3390/ijms25169055.
4
ADAMTS13 in the New Era of TTP.
Int J Mol Sci. 2024 Jul 26;25(15):8137. doi: 10.3390/ijms25158137.
5
Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review.
Ann Blood. 2023 Sep 30;8. doi: 10.21037/aob-22-29. Epub 2023 Jan 6.
6
Hemophagocytic lymphohistiocytosis is associated with deficiency and closed conformation of ADAMTS-13.
Res Pract Thromb Haemost. 2023 Dec 7;8(1):102292. doi: 10.1016/j.rpth.2023.102292. eCollection 2024 Jan.

本文引用的文献

1
Characterization of the interactions of ADAMTS13 CUB1 domain to WT- and GOF-Spacer domain by molecular dynamics simulation.
J Mol Graph Model. 2021 Dec;109:108029. doi: 10.1016/j.jmgm.2021.108029. Epub 2021 Sep 6.
2
MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding.
Biophys J. 2021 Jun 15;120(12):2543-2551. doi: 10.1016/j.bpj.2021.04.024. Epub 2021 Apr 29.
3
Crystal structure of ADAMTS13 CUB domains reveals their role in global latency.
Sci Adv. 2021 Apr 16;7(16). doi: 10.1126/sciadv.abg4403. Print 2021 Apr.
5
An Integrative Structural Biology Analysis of Von Willebrand Factor Binding and Processing by ADAMTS-13 in Solution.
J Mol Biol. 2021 Jun 25;433(13):166954. doi: 10.1016/j.jmb.2021.166954. Epub 2021 Mar 24.
6
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2021 Feb;19(2):478-488. doi: 10.1111/jth.15170. Epub 2020 Dec 31.
8
Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management.
Curr Opin Hematol. 2020 Sep;27(5):320-326. doi: 10.1097/MOH.0000000000000602.
9
Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura.
Br J Haematol. 2020 Oct;191(2):e44-e46. doi: 10.1111/bjh.16977. Epub 2020 Aug 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验